Endobiogeny: A global approach to systems biology (part 2 of 2)

Global Advances In Health and Medicine

Volumn 2, Issue 2, 2013, Pages 32-56

  Lapraz, Jean Claude ^a   Hedayat, Kamyar M ^b   Pauly, Patrice ^a  

^a Société internationale de médecine endobiogeniqueet de physiologie integrative   (France)

^b American Society of Endobiogenic Medicine and Integrative physiology   (United States)

Author keywords

Endobiogeny; Functional medicine; Reductionism; Systems biology

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE BONE ISOENZYME; ANDROGEN; ANDROSTANOLONE; BIOLOGICAL MARKER; CALCIUM ION; CORTICOTROPIN; CREATINE KINASE; ELECTROLYTE; ESTROGEN; FOLLITROPIN; HEMOGLOBIN; HYDROCORTISONE; LACTATE DEHYDROGENASE; OSTEOCALCIN; POTASSIUM ION; SEROTONIN; THYROTROPIN;

ADAPTATION RATIO; ADAPTOGEN INDEX; ADRENAL ESTROGEN AROMATIZATION INDEX; ANABOLISM INDEX; ANABOLISM RATE; ANDROGENIC INDEX; ANTIGROWTH INDEX; APOPTOSIS INDEX; BASOPHIL; BETA MELANOCYTE STIMULATING HORMONE ALPHA MELANOCYTE STIMULATING HORMONE INDEX; BIOLOGICAL MODEL; BIOMEDICINE; BLOOD CELL COUNT; BONE MARROW; BONE REMODELING INDEX; CARCINOGENESIS INDEX; CARDIOVASCULAR DISEASE; CATABOLISM ANABOLISM INDEX; CATABOLISM ANABOLISM RATIO; CATABOLISM INDEX; CORTICOADRENAL ANDROGEN RATE; CORTISOL INDEX; ENDOBIOGENY; EOSINOPHIL; ERYTHROCYTE COUNT; ESTROGEN INDEX; EVOKED HISTAMINE INDEX; GENITAL RATIO CORRECTED; GENITO THYROID INDEX; GROWTH INDEX; GROWTH INDEX CORRECTED; HORMONE ACTION; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE MOBILIZATION INDEX; LEUKOCYTOSIS; LIMIT OF QUANTITATION; LYMPHOCYTE COUNT; METABOLIC PARAMETERS; MOLECULAR DYNAMICS; MONOCYTE; MUSCULOTROPE INDEX; NECROSIS INDEX; NEUTROPHIL COUNT; NONHUMAN; PLATELET MOBILIZATION INDEX; PROAMYLOID INDEX; PROINFLAMMATORY INDEX; REVIEW; SEROTONIN INDEX; SOMATOSTATIN INDEX; STARTER INDEX; SYSTEMS BIOLOGY; THROMBOCYTE COUNT; THROMBOTIC INDEX; THYROID INDEX; THYROID YIELD;

EID: 84903584844     PISSN: 2164957X     EISSN: 21649561     Source Type: Journal    
DOI: 10.7453/gahmj.2013.013     Document Type: Review

References (304)

1. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. May 15 2008;473(2):231-236.
2. Kim YS, Paik IY, Rhie YJ, Suh SH. Integrative physiology: defined novel metabolic roles of osteocalcin. J Korean Med Sci. Jul 2010;25(7):985-991.
3. Lee NK, Sowa H, Hinoi E, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. Aug 10 2007;130(3):456-469.
4. Palis J, Yoder MC. Yolk-sac hematopoiesis: the first blood cells of mouse and man. Exp Hematol. Aug 2001;29(8):927-936.
5. Moritz KM, Lim GB, Wintour EM. Developmental regulation of erythropoietin and erythropoiesis. Am J Physiol. Dec 1997;273(6 Pt 2):R1829-1844.
6. Bleiberg I, Perah G, Feldman M. Effect of testosterone on the formation of erythroid spleen colonies from fetal liver precursor cells. Blood. Feb 1973;41(2):285-291.
7. Congote LF. Regulation of fetal liver erythropoiesis. J Steroid Biochem. May 1977;8(5):423-428.
8. Fisher DA. The unique endocrine milieu of the fetus. J Clin Invest. Sep 1986;78(3):603-611.
9. Gardner FH, Pringle JC, Jr. Androgens and erythropoiesis. I. Preliminary clinical observations. Arch Intern Med. Jun 1961;107:846-862.
10. Fisher JW, Samuels AI, Malgor LA. Androgens and erythropoiesis. Isr J Med Sci. Jul-Aug 1971;7(7):892-900.
11. Gardner FH, Gorshein D. Regulation of erythropoiesis by androgens. Trans Am Clin Climatol Assoc. 1973;84:60-70.
12. Evens RP, Amerson AB. Androgens and erythropoiesis. J Clin Pharmacol. Feb-Mar 1974;14(2):94-101.
13. ANDROGENS and erythropoiesis. Br Med J. Dec 14 1957;2(5058):1422-1423.
14. Alexanian R. Erythropoietin and erythropoiesis in anemic man following androgens. Blood. Apr 1969;33(4):564-572.
15. Gerbino PP. Actions of androgens on erythropoiesis. Hosp Top. Sep-Oct 1974;52(8):28,55.
16. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF. Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod. Dec 2007;22(12):3197-3203.
17. Quaschning T, Ruschitzka F, Stallmach T, et al. Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J. Feb 2003;17(2):259-261.
18. Pavlovic-Kentera V, Basara N, Jerkic M, et al. Erythrocytosis in spontaneously hypertensive rats. Exp Hematol. Dec 1988;16(11):950-953.
19. Sen S, Hoffman GC, Stowe NT, Smeby RR, Bumpus FM. Erythrocytosis in spontaneously hypertensive rats. J Clin Invest. Mar 1972;51(3):710-714.
20. D'Ascenzo S, Millimaggi D, Di Massimo C, et al. Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett. Mar 8 2007;169(2):129-136.
21. Dickerman RD, McConathy WJ, Zachariah NY. Testosterone, sex hormonebinding globulin, lipoproteins, and vascular disease risk. J Cardiovasc Risk. Oct-Dec 1997;4(5-6):363-366.
22. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. Dec 1996;17(12):1912.
23. Winkler UH. Effects of androgens on haemostasis. Maturitas. Jul 1996;24(3):147-155.
24. Halushka PV, Masuda A, Matsuda K. The Gordon Wilson Lecture. Regulation of thromboxane A2 receptors by testosterone: implications for steroid abuse and cardiovascular disease. Trans Am Clin Climatol Assoc. 1994;105:95-103.
25. Noh JY, Lim KM, Bae ON, et al. Procoagulant and prothrombotic activation of human erythrocytes by phosphatidic acid. Am J Physiol Heart Circ Physiol. Aug 2010;299(2):H347-355.
26. Santos MT, Valles J, Lago A, et al. Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. J Thromb Haemost. Apr 2008;6(4):615-621.
27. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation. Feb 3 1998;97(4):350-355.
28. Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB. Prothrombotic effects of erythrocytes on platelet reactivity. Reduction by aspirin. Circulation. Jan 7 1997;95(1):63-68.
29. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. Apr 2006;91(4):1305-1308.
30. Lopez-Bermejo A, Diaz M, Moran E, de Zegher F, Ibanez L. A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. Diabetes Care. Jul 2010;33(7):1544-1548.
31. Smith R, Mann N, Makelainen H, Roper J, Braue A, Varigos G. A pilot study to determine the short-term effects of a low glycemic load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial. Mol Nutr Food Res. Jun 2008;52(6):718-726.
32. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. Jun 2000;21(11):890-894.
33. Jones RD, Malkin CJ, Channer KS, Jones TH. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: further supportive data. J Clin Endocrinol Metab. Mar 2003;88(3):1403-1404; author reply 1404.
34. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. Aug 2002;87(8):3632-3639.
35. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab. Mar 2006;91(3):843-850.
36. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. Aug 19 1998;280(7):605-613.
37. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. Jul 17 2002;288(3):321-333.
38. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. Aug 21 2002;288(7):872-881.
39. Jenkins JS. The voice of the castrato. Lancet. Jun 20 1998;351(9119):1877-1880.
40. Paternostro G. Longevity and testosterone. Nature. Mar 31 1994;368(6470):408.
41. Stenholm S, Metter EJ, Roth GS, et al. Relationship between plasma ghrelin, insulin, leptin, interleukin 6, adiponectin, testosterone and longevity in the Baltimore Longitudinal Study of Aging. Aging Clin Exp Res. Apr 2011;23(2):153-158.
42. Toulis KA, Goulis DG, Mintziori G, et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. Nov-Dec 2011;17(6):741-760.
43. Talbott EO, Zborowskii JV, Boudraux MY. Do women with polycystic ovary syndrome have an increased risk of cardiovascular disease? Review of the evidence. Minerva Ginecol. Feb 2004;56(1):27-39.
44. Loucks TL, Talbott EO, McHugh KP, Keelan M, Berga SL, Guzick DS. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fertil Steril. Sep 2000;74(3):547-552.
45. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). May 2000;52(5):595-600.
46. Dogramaci AC, Balci DD, Balci A, et al. Is androgenetic alopecia a risk for atherosclerosis? J Eur Acad Dermatol Venereol. Feb 23 2009.
47. Rasmuson S, Nasman B, Carlstrom K, Olsson T. Increased levels of adrenocortical and gonadal hormones in mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;13(2):74-79.
48. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. Jun 2003;24(3):313-340.
49. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in nongenomic androgen actions. Mol Endocrinol. Oct 2002;16(10):2181-2187.
50. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. May 2008;29(2):182-198.
51. Reisner EH, Jr. Tissue culture of bone marrow. II. Effect of steroid hormones on hematopoiesis in vitro. Blood. Apr 1966;27(4):460-469.
52. Branch DW. Physiologic adaptations of pregnancy. Am J Reprod Immunol. Oct-Dec 1992;28(3-4):120-122.
53. Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM. The hypothalamic-pituitary- gonadal axis: immune function and autoimmunity. J Endocrinol. Mar 2003;176(3):293-304.
54. Masood DE, Roach EC, Beauregard KG, Khalil RA. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab. Oct 2010;11(8):693-714.
55. Hammond CB, Soules M. Clinical significance of estrogen metabolism and physiology. Contemp Ob/Gyn 1978;11:41.
56. Gore AC. Neuroendocrine targets of endocrine disruptors. Hormones (Athens). Jan-Mar 2010;9(1):16-27.
57. Dickerson SM, Gore AC. Estrogenic environmental endocrine-disrupting chemical effects on reproductive neuroendocrine function and dysfunction across the life cycle. Rev Endocr Metab Disord. Jun 2007;8(2):143-159.
58. Matthews J, Gustafsson JA. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv. Aug 2003;3(5):281-292.
59. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal. 2008;6:e003.
60. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. Nov 1 2008;113(9):2385-2397.
61. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. Jan 1998;19(1):1-27.
62. Pfeffer U, Fecarotta E, Vidali G. Coexpression of multiple estrogen receptor variant messenger RNAs in normal and neoplastic breast tissues and in MCF-7 cells. Cancer Res. May 15 1995;55(10):2158-2165.
63. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. Sep 2001;45(3 Suppl):S116-124.
64. Feigelson HS, McKean-Cowdin R, Pike MC, et al. Cytochrome P450c17alpha gene (CYP17) polymorphism predicts use of hormone replacement therapy. Cancer Res. Aug 15 1999;59(16):3908-3910.
65. al-Azzawi F, Wahab M. Estrogen and colon cancer: current issues. Climacteric. Mar 2002;5(1):3-14.
66. Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med. Nov 1999;8(9):1155-1166.
67. Xu X, Thomas ML. Biphasic actions of estrogen on colon cancer cell growth: possible mediation by high- and low-affinity estrogen binding sites. Endocrine. Sep 1995;3(9):661-665.
68. Muti P. The role of endogenous hormones in the etiology and prevention of breast cancer: the epidemiological evidence. Recent Results Cancer Res. 2005;166:245-256.
69. Fuster JJ, Andres V. Telomere biology and cardiovascular disease. Circ Res. Nov 24 2006;99(11):1167-1180.
70. Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:984013.
71. von Dadelszen P, Watson RW, Noorwali F, et al. Maternal neutrophil apoptosis in normal pregnancy, preeclampsia, and normotensive intrauterine growth restriction. Am J Obstet Gynecol. Aug 1999;181(2):408-414.
72. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. Mar 2006;6(3):173-182.
73. Park JE, Barbul A. Understanding the role of immune regulation in wound healing. Am J Surg. May 2004;187(5A):11S-16S.
74. Hussein OA, El-Toukhy MA, El-Rahman HS. Neutrophil CD64 expression in inflammatory autoimmune diseases: its value in distinguishing infection from disease flare. Immunol Invest. 2010;39(7):699-712.
75. Nemeth T, Futosi K, Hably C, et al. Neutrophil functions and autoimmune arthritis in the absence of p190RhoGAP: generation and analysis of a novel null mutation in mice. J Immunol. Sep 1 2010;185(5):3064-3075.
76. Liu Z, Giudice GJ, Zhou X, et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest. Sep 1 1997;100(5):1256-1263.
77. Hofman PM. Pathobiology of the neutrophil-intestinal epithelial cell interaction: role in carcinogenesis. World J Gastroenterol. Dec 14 2010;16(46):5790-5800.
78. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. Feb 17 2001;357(9255):539-545.
79. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. Feb 2008;18(1):3-10.
80. Borrello MG, Degl'Innocenti D, Pierotti MA. Inflammation and cancer: the oncogene-driven connection. Cancer Lett. Aug 28 2008;267(2):262-270.
81. Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. Apr 2008;108(3):389-397.
82. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. Sep 2008;173(3):600-609.
83. Pietrogrande L, Raimondo E, Fossali A, Zaolino C. Biological and pharmacological factors influencing the fracture healing. Aging Clin Exp Res. Apr 2011;23(2 Suppl):65-68.
84. Campbell L, Emmerson E, Davies F, et al. Estrogen promotes cutaneous wound healing via estrogen receptor beta independent of its antiinflammatory activities. J Exp Med. Aug 30 2010;207(9):1825-1833.
85. Hardman MJ, Ashcroft GS. Estrogen, not intrinsic aging, is the major regulator of delayed human wound healing in the elderly. Genome Biol. 2008;9(5):R80.
86. Mills SJ, Ashworth JJ, Gilliver SC, Hardman MJ, Ashcroft GS. The sex steroid precursor DHEA accelerates cutaneous wound healing via the estrogen receptors. J Invest Dermatol. Nov 2005;125(5):1053-1062.
87. Ashcroft GS, Mills SJ, Lei K, et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest. May 2003;111(9):1309-1318.
88. Ashcroft GS, Greenwell-Wild T, Horan MA, Wahl SM, Ferguson MW. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol. Oct 1999;155(4):1137-1146.
89. Walker SE. Estrogen and autoimmune disease. Clin Rev Allergy Immunol. Feb 2011;40(1):60-65.
90. Ostensen M. Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus. Ann N Y Acad Sci. Jun 22 1999;876:131-143; discussion 144.
91. Crafts RG. The effects of estrogens on the bone marrow of adult female dogs. Blood. Mar 1948;3(3):276-285.
92. Molloy EJ, O'Neill AJ, Grantham JJ, et al. Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood. Oct 1 2003;102(7):2653-2659.
93. Harkonen PL, Vaananen HK. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci. Nov 2006;1089:218-227.
94. Ben-Hur H, Mor G, Insler V, et al. Menopause is associated with a significant increase in blood monocyte number and a relative decrease in the expression of estrogen receptors in human peripheral monocytes. Am J Reprod Immunol. Dec 1995;34(6):363-369.
95. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. Mar 2007;81(3):584-592.
96. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz). Oct 2010;58(5):355-364.
97. Sweeten TL, Posey DJ, McDougle CJ. High blood monocyte counts and neopterin levels in children with autistic disorder. Am J Psychiatry. Sep 2003;160(9):1691-1693.
98. Rivier A, Pene J, Rabesandratana H, Chanez P, Bousquet J, Campbell AM. Blood monocytes of untreated asthmatics exhibit some features of tissue macrophages. Clin Exp Immunol. May 1995;100(2):314-318.
99. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock HW. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood. Nov 15 1993;82(10):3170-3176.
100. Seli E, Selam B, Mor G, Kayisli UA, Pehlivan T, Arici A. Estradiol regulates monocyte chemotactic protein-1 in human coronary artery smooth muscle cells: a mechanism for its antiatherogenic effect. Menopause. Jul-Aug 2001;8(4):296-301.
101. Hong YJ, Jeong MH, Ahn Y, et al. Relationship between peripheral monocytosis and nonrecovery of left ventricular function in patients with left ventricular dysfunction complicated with acute myocardial infarction. Circ J. Aug 2007;71(8):1219-1224.
102. Beran M, Shen Y, Onida F, Wen S, Kantarjian H, Estey E. Prognostic significance of monocytosis in patients with myeloproliferative disorders. Leuk Lymphoma. Mar 2006;47(3):417-423.
103. Economopoulos T, Stathakis N, Maragoyannis Z, Gardikas E, Dervenoulas J. Myelodysplastic syndrome. Clinical and prognostic significance of monocyte count, degree of blastic infiltration, and ring sideroblasts. Acta Haematol. 1981;65(2):97-102.
104. Fenaux P, Beuscart R, Lai JL, Jouet JP, Bauters F. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol. Sep 1988;6(9):1417-1424.
105. Jaworkowsky LI, Solovey DY, Rhausova LY, Udris OY. Monocytosis as a sign of subsequent leukemia in patients with cytopenias (preleukemia). Folia Haematol Int Mag Klin Morphol Blutforsch. 1983;110(3):395-401.
106. Owen G, Lewis IJ, Morgan M, Robinson A, Stevens RF. Prognostic factors in juvenile chronic granulocytic leukaemia. Br J Cancer Suppl. Aug 1992;18:S68-71.
107. Takasaki Y, Iwanaga M, Tsukasaki K, et al. Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/ lymphoma (ATLL). Leuk Res. Jun 2007;31(6):751-757.
108. Simon JA. Safety of estrogen/androgen regimens. J Reprod Med. Mar 2001;46(3 Suppl):281-290.
109. McCrohon JA, Jessup W, Handelsman DJ, Celermajer DS. Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation. May 4 1999;99(17):2317-2322.
110. Thorn GW, Forsham PH, et al. A test for adrenal cortical insufficiency; the response to pituitary andrenocorticotropic hormone. J Am Med Assoc. Jul 17 1948;137(12):1005-1009.
111. Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev. Jun 1999;51(2):213-340.
112. Beishuizen A, Thijs LG. Relative adrenal failure in intensive care: an identifiable problem requiring treatment? Best Pract Res Clin Endocrinol Metab. Dec 2001;15(4):513-531.
113. Beishuizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet. May 15 1999;353(9165):1675-1676.
114. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. Jul 2000;55(7):603-613.
115. Sabag N, Castrillon MA, Tchernitchin A. Cortisol-induced migration of eosinophil leukocytes to lymphoid organs. Experientia. May 15 1978;34(5):666-667.
116. Ohtsu H. Progress in allergy signal research on mast cells: the role of histamine in immunological and cardiovascular disease and the transporting system of histamine in the cell. J Pharmacol Sci. Mar 2008;106(3):347-353.
117. Dimova-Yaneva D, Russell D, Main M, Brooker RJ, Helms PJ. Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis. Clin Exp Allergy. Apr 2004;34(4):555-558.
118. Garofalo R, Dorris A, Ahlstedt S, Welliver RC. Peripheral blood eosinophil counts and eosinophil cationic protein content of respiratory secretions in bronchiolitis: relationship to severity of disease. Pediatr Allergy Immunol. May 1994;5(2):111-117.
119. Kim CK, Kim SW, Kim YK, et al. Bronchoalveolar lavage eosinophil cationic protein and interleukin-8 levels in acute asthma and acute bronchiolitis. Clin Exp Allergy. May 2005;35(5):591-597.
120. Kim HH, Lee MH, Lee JS. Eosinophil cationic protein and chemokines in nasopharyngeal secretions of infants with respiratory syncytial virus (RSV) bronchiolitis and non-RSV bronchiolitis. J Korean Med Sci. Feb 2007;22(1):37-42.
121. Phipps S, Lam CE, Mahalingam S, et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood. Sep 1 2007;110(5):1578-1586.
122. Priftis KN, Papadopoulou A, Liatsis E, Katsikas D, Nicolaidou P, Kanariou M. Serum eosinophil cationic protein and CD23 in acute RSV bronchiolitis. Med Sci Monit. Oct 2005;11(10):CR493-497.
123. Rosenberg HF. RNase A ribonucleases and host defense: an evolving story. J Leukoc Biol. May 2008;83(5):1079-1087.
124. Rosenberg HF, Domachowske JB. Eosinophils, ribonucleases and host defense: solving the puzzle. Immunol Res. 1999;20(3):261-274.
125. Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol. Nov 2001;70(5):691-698.
126. Thorne KJ, Richardson BA, Veith MC, Tai PC, Spry CJ, Butterworth AE. Partial purification and biological properties of an eosinophil-activating factor. Eur J Immunol. Nov 1985;15(11):1083-1091.
127. Mingomataj EC. Eosinophil-induced prognosis improvement of solid tumors could be enabled by their vesicle-mediated barrier permeability induction. Med Hypotheses. 2008;70(3):582-584.
128. Aguilera-Aguirre L, Bacsi A, Saavedra-Molina A, Kurosky A, Sur S, Boldogh I. Mitochondrial dysfunction increases allergic airway inflammation. J Immunol. Oct 15 2009;183(8):5379-5387.
129. Heidenfelder B, Johnson M, Hudgens E, et al. Increased plasma reactive oxidant levels and their relationship to blood cells, total IgE, and allergen-specific IgE levels in asthmatic children. J Asthma. Sep 2009;46(7):687-691.
130. Kahn JE, Dutoit-Lefevre V, Duban-Deweer S, et al. Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. J Proteome Res. Feb 8 2011.
131. Kuo Chou TN, Li YS, Lue KH, et al. Genetic polymorphism of manganese superoxide dismutase is associated with childhood asthma. J Asthma. Jun 2010;47(5):532-538.
132. Lee YA, Shin MH. Mitochondrial respiration is required for activation of ERK1/2 and caspase-3 in human eosinophils stimulated with hydrogen peroxide. J Investig Allergol Clin Immunol. 2009;19(3):188-194.
133. Tripathi P, Nair S, Singh BP, Arora N. Mutated glutathione S-transferase in combination with reduced glutathione shows a synergistic effect in ameliorating oxidative stress and airway inflammation. Free Radic Biol Med. Mar 15 2010;48(6):839-844.
134. Jutel M, Blaser K, Akdis CA. The role of histamine in regulation of immune responses. Chem Immunol Allergy. 2006;91:174-187.
135. Jutel M, Watanabe T, Akdis M, Blaser K, Akdis CA. Immune regulation by histamine. Curr Opin Immunol. Dec 2002;14(6):735-740.
136. Ochensberger B, Daepp GC, Rihs S, Dahinden CA. Human blood basophils produce interleukin-13 in response to IgE-receptor-dependent and -independent activation. Blood. Oct 15 1996;88(8):3028-3037.
137. Lantz CS, Boesiger J, Song CH, et al. Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. Mar 5 1998;392(6671):90-93.
138. Falcone FH, Haas H, Gibbs BF. The human basophil: a new appreciation of its role in immune responses. Blood. Dec 15 2000;96(13):4028-4038.
139. Fauci AS, Dale DC. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest. Jan 1974;53(1):240-246.
140. Haynes BF, Fauci AS. The differential effect of in vivo hydrocortisone on the kinetics of subpopulations of human peripheral blood thymus-derived lymphocytes. J Clin Invest. Mar 1978;61(3):703-707.
141. Gatti G, Cavallo R, Sartori ML, et al. Inhibition by cortisol of human natural killer (NK) cell activity. J Steroid Biochem. Jan 1987;26(1):49-58.
142. Masera R, Gatti G, Sartori ML, et al. Involvement of Ca2+-dependent pathways in the inhibition of human natural killer (NK) cell activity by cortisol. Immunopharmacology. Jul-Aug 1989;18(1):11-22.
143. Mendelsohn J, Multer MM, Bernheim JL. Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. Clin Exp Immunol. Jan 1977;27(1):127-134.
144. Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol. Dec 1985;121(3):531-551.
145. Gaberscek S, Zaletel K. Thyroid physiology and autoimmunity in pregnancy and after delivery. Expert Rev Clin Immunol. Sep 2011;7(5):697-706; quiz 707.
146. Kuijpens JL, De Hann-Meulman M, Vader HL, Pop VJ, Wiersinga WM, Drexhage HA. Cell-mediated immunity and postpartum thyroid dysfunction: a possibility for the prediction of disease? J Clin Endocrinol Metab. Jun 1998;83(6):1959-1966.
147. Gerhard I, Waibel S, Daniel V, Runnebaum B. Impact of heavy metals on hormonal and immunological factors in women with repeated miscarriages. Hum Reprod Update. May-Jun 1998;4(3):301-309.
148. Hoermann R, Eckl W, Hoermann C, Larisch R. Complex relationship between free thyroxine and TSH in the regulation of thyroid function. Eur J Endocrinol. Jun 2010;162(6):1123-1129.
149. Christ-Crain M, Meier C, Huber P, Zulewski H, Staub JJ, Muller B. Effect of restoration of euthyroidism on peripheral blood cells and erythropoietin in women with subclinical hypothyroidism. Hormones (Athens). Oct-Dec 2003;2(4):237-242.
150. Papic M, Stein-Streilein J, Zakarija M, McKenzie JM, Guffee J, Fletcher MA. Suppression of peripheral blood natural killer cell activity by excess thyroid hormone. J Clin Invest. Feb 1987;79(2):404-408.
151. Bizzozero J. Ueber einen neuen Formbestandtheil des Blutes und dessen Rolle bei der Thrombose und der Blutgerinnung. Virchows Archiv. 1882;90(2):261-332.
152. Schmidt MB, Chen EH, Lynch SE. A review of the effects of insulin-like growth factor and platelet derived growth factor on in vivo cartilage healing and repair. Osteoarthritis Cartilage. May 2006;14(5):403-412.
153. Tennant M, McGeachie JK. Platelet-derived growth factor and its role in atherogenesis: a brief review. Aust N Z J Surg. Jul 1991;61(7):482-488.
154. Adelson E, Rheingold JJ, Crosby WH. The platelet as a sponge: a review. Blood. Jun 1961;17:767-774.
155. Gershon MD. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. Nov 2004;20 Suppl 7:3-14.
156. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin- prolactin interactions. Neuropsychopharmacology. May 2004;29(5):833-846.
157. Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med. Jun 25 2007;167(12):1246-1251.
158. Haney EM, Warden SJ. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact. Apr-Jun 2008;8(2):133-145.
159. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol. Sep 2004;25(9):489-495.
160. Saxena SP, McNicol A, Brandes LJ, Becker AB, Gerrard JM. A role for intracellular histamine in collagen-induced platelet aggregation. Blood. Jan 15 1990;75(2):407-414.
161. Eckardt KU. Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant. Jun 2005;20 Suppl 6:vi16-20.
162. Anand IS. Heart failure and anemia: mechanisms and pathophysiology. Heart Fail Rev. Dec 2008;13(4):379-386.
163. Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15 Suppl 3:14-18.
164. Glick G, Plauth WH, Jr., Braunwald E. Role of the Autonomic Nervous System in the Circulatory Response to Acutely Induced Anemia in Unanesthetized Dogs. J Clin Invest. Nov 1964;43:2112-2124.
165. Voorhess ML, Stuart MJ, Stockman JA, Oski FA. Iron deficiency anemia and increased urinary norepinephrine excretion. J Pediatr. Apr 1975;86(4):542-547.
166. Wagner A, Fortier N, Giroux A, Lukes J, Snyder LM. Catecholamines in adult iron deficiency patients. Experientia. May 15 1979;35(5):681-682.
167. Groeneveld D, Smeets HG, Kabra PM, Dallman PR. Urinary catecholamines in iron-deficient rats at rest and following surgical stress. Am J Clin Nutr. Aug 1985;42(2):263-269.
168. Hwang YC, Jeong IK, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced beta-cell function in middle-aged male subjects. Diabetes Metab Res Rev. Nov 2009;25(8):768-772.
169. Im JA, Yu BP, Jeon JY, Kim SH. Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta. Oct 2008;396(1-2):66-69.
170. Kindblom JM, Ohlsson C, Ljunggren O, et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res. May 2009;24(5):785-791.
171. Munzer T, Rosen CJ, Harman SM, et al. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men. Am J Physiol Endocrinol Metab. May 2006;290(5):E1006-1013.
172. Kulak CA, Baz-Hecht M, Nieves J, Shen V, Lindsay R, Cosman F. Responses of Urinary N-Telopeptide and Renal Calcium Handling to PTH Infusion after Treatment with Estrogen, Raloxifene, and Tamoxifen. Calcif TissueInt. Feb 5 2012.
173. Ernst M, Schmid C, Froesch ER. Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci U S A. Apr 1988;85(7):2307-2310.
174. DiSilvio L, Jameson J, Gamie Z, Giannoudis PV, Tsiridis E. In vitro evaluation of the direct effect of estradiol on human osteoblasts (HOB) and human mesenchymal stem cells (h-MSCs). Injury. Sep 2006;37 Suppl 3:S33-42.
175. Baqi L, Payer J, Killinger Z, et al. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women. Endocr Regul. Apr 2010;44(2):57-63.
176. Baqi L, Payer J, Killinger Z, et al. The level of TSH appeared favourable in maintaining bone mineral density in postmenopausal women. Endocr Regul. Jan 2010;44(1):9-15.
177. Guo CY, Weetman AP, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin Endocrinol (Oxf). Mar 1997;46(3):301-307.
178. Tarle M. Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents. Urol Res. 1991;19(1):39-44.
179. Yeung F, Law WK, Yeh CH, et al. Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J Biol Chem. Jan 25 2002;277(4):2468-2476.
180. Moss DW. Diagnostic aspects of alkaline phosphatase and its isoenzymes. Clin Biochem. Aug 1987;20(4):225-230.
181. Orimo H. The mechanism of mineralization and the role of alkaline phosphatase in health and disease. J Nippon Med Sch. Feb 2010;77(1):4-12.
182. Magnusson P, Degerblad M, Saaf M, Larsson L, Thoren M. Different responses of bone alkaline phosphatase isoforms during recombinant insulin-like growth factor-I (IGF-I) and during growth hormone therapy in adults with growth hormone deficiency. J Bone Miner Res. Feb 1997;12(2):210-220.
183. Stepan J, Havranek T, Formankova J, Skrha J, Skrha F, Pacovsky V. Bone isoenzyme of serum alkaline phosphatase in diabetes mellitus. Clin Chim Acta. Jul 17 1980;105(1):75-81.
184. Aliev M, Guzun R, Karu-Varikmaa M, Kaambre T, Wallimann T, Saks V. Molecular System Bioenergics of the Heart: Experimental Studies of Metabolic Compartmentation and Energy Fluxes versus Computer Modeling. Int J Mol Sci. 2011;12(12):9296-9331.
185. Wallimann T, Hemmer W. Creatine kinase in non-muscle tissues and cells. Mol Cell Biochem. Apr-May 1994;133-134:193-220.
186. Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin Chem Lab Med. Jun 2010;48(6):757-767.
187. Banfi G, Colombini A, Lombardi G, Lubkowska A. Metabolic markers in sports medicine. Adv Clin Chem. 2012;56:1-54.
188. Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. Oct 2007;2(3):210-218.
189. Newsholme EA, Beis I, Leech AR, Zammit VA. The role of creatine kinase and arginine kinase in muscle. Biochem J. Jun 15 1978;172(3):533-537.
190. Khan HA, Alhomida AS, Sobki SH, Moghairi AA, Koronki HE. Blood cell counts and their correlation with creatine kinase and C-reactive protein in patients with acute myocardial infarction. Int J Clin Exp Med. 2012;5(1):50-55.
191. Karras DJ, Kane DL. Serum markers in the emergency department diagnosis of acute myocardial infarction. Emerg Med Clin North Am. May 2001;19(2):321-337.
192. Green SM, Vowels J, Waterman B, Rothrock SG, Kuniyoshi G. Leukocytosis: a new look at an old marker for acute myocardial infarction. Acad Emerg Med. Nov 1996;3(11):1034-1041.
193. Paul GK, Sen B, Bari MA, et al. Correlation of platelet count and acute ST-elevation in myocardial infarction. Mymensingh Med J. Jul 2010;19(3):469-473.
194. Vermeulen RC, Kurk RM, Visser FC, Sluiter W, Scholte HR. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J Transl Med. 2010;8:93.
195. Diaz-Olmos R, Nogueira AC, Penalva DQ, Lotufo PA, Bensenor IM. Frequency of subclinical thyroid dysfunction and risk factors for cardiovascular disease among women at a workplace. Sao Paulo Med J. Jan 2010;128(1):18-23.
196. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess allcause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. Sep 2008;159(3):329-341.
197. Rodondi N, Bauer DC, Cappola AR, et al. Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health study. J Am Coll Cardiol. Sep 30 2008;52(14):1152-1159.
198. Burnett JR, Crooke MJ, Delahunt JW, Feek CM. Serum enzymes in hypothyroidism. N Z Med J. Sep 14 1994;107(985):355-356.
199. Saha B, Maity C. Alteration of serum enzymes in primary hypothyroidism. Clin Chem Lab Med. Jun 2002;40(6):609-611.
200. Hekimsoy Z, Oktem IK. Serum creatine kinase levels in overt and subclinical hypothyroidism. Endocr Res. 2005;31(3):171-175.
201. Beyer IW, Karmali R, Demeester-Mirkine N, Cogan E, Fuss MJ. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid. Nov 1998;8(11):1029-1031.
202. Chazov EI, Smirnov VN, Zisko AP, Stark VM. Serum lactic dehydrogenase isoenzyme patterns in coronary atherosclerosis. J Atheroscler Res. Mar-Apr 1969;9(2):203-207.
203. Karacalioglu O, Arslan Z, Kilic S, Ozturk E, Ozguven M. Baseline serum levels of cardiac biomarkers in patients with stable coronary artery disease. Biomarkers. Sep-Oct 2007;12(5):533-540.
204. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. Sep 2009;92(3):329-333.
205. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. Mar 15 2006;107(6):2279-2285.
206. Mansuroglu D, Omeroglu SN, Izgi A, et al. LDH levels and left atrial ultrastructural chances in patients with mitral paraprosthetic regurgitation. J Card Surg. May-Jun 2005;20(3):229-233.
207. Bien E, Balcerska A. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer]. Med Wieku Rozwoj. Oct-Dec 2004;8(4 Pt 2):1081-1089.
208. Pui CH, Dodge RK, Dahl GV, et al. Serum lactic dehydrogenase level has prognostic value in childhood acute lymphoblastic leukemia. Blood. Oct 1985;66(4):778-782.
209. Draoui N, Feron O. Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments. Dis Model Mech. Nov 2010;4(6):727-732.
210. Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid. Dec 1997;7(6):879-884.
211. Robbins RJ, Leidy JW, Jr., Landon RM. The effects of growth hormone, prolactin, corticotropin, and thyrotropin on the production and secretion of somatostatin by hypothalamic cells in vitro. Endocrinology. Aug 1985;117(2):538-543.
212. Banu KS, Aruldhas MM. Sex steroids regulate TSH-induced thyroid growth during sexual maturation in Wistar rats. Exp Clin Endocrinol Diabetes. Jan 2002;110(1):37-42.
213. Morley JE. Extrahypothalamic thyrotropin releasing hormone (TRH) -- its distribution and its functions. Life Sci. Oct 29 1979;25(18):1539-1550.
214. Mortimer CH, Besser GM, McNeilly AS, Tunbridge WM, Gomez-Pan A, Hall R. Interaction between secretion of the gonadotrophins, prolactin, growth hormone, thyrotrophin and corticosteroids in man: the effects of LH FSHRH, TRH and hypoglycaemia alone and in combination. Clin Endocrinol (Oxf). Oct 1973;2(4):317-326.
215. Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Kasper DL, Harrison TR, eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill, Medical Pub. Division; 2005:2 v. (xxvii, 2607, [2615, 2128] p.).
216. Durand D, Pampillo M, Caruso C, Lasaga M. Role of metabotropic glutamate receptors in the control of neuroendocrine function. Neuropharmacology. Sep 2008;55(4):577-583.
217. Caldwell JD, Suleman F, Chou SH, Shapiro RA, Herbert Z, Jirikowski GF. Emerging roles of steroid-binding globulins. Horm Metab Res. Apr 2006;38(4):206-218.
218. Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost. Sep 1 1993;70(3):506-513.
219. Shah BH, Lashari I, Rana S, Saeed O, Rasheed H, Arshad Saeed S. Synergistic interaction of adrenaline and histamine in human platelet aggregation is mediated through activation of phospholipase, map kinase and cyclo-oxygenase pathways. Pharmacol Res. Nov 2000;42(5):479-483.
220. Erfurth EM, Ericsson UB. The role of estrogen in the TSH and prolactin responses to thyrotropin-releasing hormone in postmenopausal as compared to premenopausal women. Horm Metab Res. Nov 1992;24(11):528-531.
221. Tahboub R, Arafah BM. Sex steroids and the thyroid. Best Pract Res Clin Endocrinol Metab. Dec 2009;23(6):769-780.
222. Shiraki M, Orimo H. [The effect of estrogen and, sex-steroids and thyroid hormone preparation on bone mineral density in senile osteoporosis--a comparative study of the effect of 1 alpha-hydroxycholecalciferol (1 alpha- OHD3) on senile osteoporosis]. Nihon Naibunpi Gakkai Zasshi. Feb 20 1991;67(2):84-95.
223. Sekulic M, Sosic-Jurjevic B, Filipovic B, Manojlovic-Stojanoski M, Milosevic V. Immunoreactive TSH cells in juvenile and peripubertal rats after estradiol and human chorionic gonadotropin treatment. Acta Histochem. 2006;108(2):117-123.
224. McGrowder DA, Fraser YP, Gordon L, Crawford TV, Rawlins JM. Serum creatine kinase and lactate dehydrogenase activities in patients with thyroid disorders. Niger J Clin Pract. 2011 Oct-Dec;14(4):454-9. doi: 10.4103/1119- 3077.91755.
225. Zitzmann M, Brune M, Kornmann B, Gromoll J, Junker R, Nieschlag E. The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf). Nov 2001;55(5):649-657.
226. Scopacasa F, Horowitz M, Wishart JM, Morris HA, Chatterton BE, Need AG. The relation between bone density, free androgen index, and estradiol in men 60 to 70 years old. Bone. Jul 2000;27(1):145-149.
227. McKenna TJ, Cunningham SK, Loughlin T. The adrenal cortex and virilization. Clin Endocrinol Metab. Nov 1985;14(4):997-1020.
228. Ghizzoni L, Mastorakos G, Vottero A. Endotext: Chapter 3: Adrenal Androgens; 2003: http://www.endotext.org/adrenal/adrenal3/adrenalframe3. htm Accessed 1/1/2012.
229. Ryan KJ. Biochemistry of aromatase: significance to female reproductive physiology. Cancer Res. Aug 1982;42(8 Suppl):3342s-3344s.
230. Angelis M, Yu M, Takanishi D, Hasaniya NW, Brown MR. Eosinophilia as a marker of adrenal insufficiency in the surgical intensive care unit. J Am Coll Surg. Dec 1996;183(6):589-596.
231. Meya DB, Katabira E, Otim M, et al. Functional adrenal insufficiency among critically ill patients with human immunodeficiency virus in a resourcelimited setting. Afr Health Sci. Jun 2007;7(2):101-107.
232. Mouloudi E, Katsanoulas C, Vrochides D, Giasnetsova T, Papageorghiou C, Gritsi-Gerogianni N. Eosinophilia as a marker of adrenal insufficiency in critically ill patients with severe septic shock: 1-year prospective study. Critical Care. 2008;12(Suppl 5)(P9).
233. Quinn RE. Acute adrenal insufficiency and acute myocardial infarction; simultaneous occurrence associated with marked eosinophilia and recovery. N Engl J Med. Jun 7 1956;254(23):1068-1072.
234. Bauer ME, Jeckel CM, Luz C. The role of stress factors during aging of the immune system. Ann N Y Acad Sci. Feb 2009;1153:139-152.
235. Beishuizen A, Thijs LG, Vermes I. Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Crit Care. Oct 2002;6(5):434-438.
236. Basu Mallik KC, Bhattacharya DK. The role of histamine in tropical eosinophilia. J Indian Med Assoc. Oct 1 1959;33:260-263.
237. Bharadwaj TP, Gaitonde BB, Jhala HI. Histamine and tropical eosinophilia. Indian J Med Res. Jul 1959;47:377-381.
238. el-Hawey AM, Selim AS, Mousa AH. Plasma histamine level and its relation to blood eosinophilia in bilharzialcases. J Egypt Med Assoc. 1970;53(7):530-537.
239. Ganatra RD, Gaitonde BB, Sheth UK. Blood levels of histamine in relation to eosinophilia. Indian J Med Sci. Apr 1960;14:328-334.
240. Hungerford GF. Role of Histamine in Producing the Eosinophilia of Magnesium Deficiency. Proc Soc Exp Biol Med. Jan 1964;115:182-185.
241. Josefsson B. Studies on eosinophil granulocytes. V. Evidence against the role of histamine as a mediator of eosinophilia in the uterus of the rat. Acta Endocrinol (Copenh). Jul 1968;58(3):532-536.
242. Litt M. Studies in experimental eosinophilia. X. Dissociation of histamineinduced vascular eosinophilia and antigen-induced tissue eosinophilia. J Reticuloendothel Soc. Aug 1973;14(2):158-170.
243. Litt M. Studies in experimental eosinophilia. XI. Dependence of eosinophilia, apparently induced by histamine, on acidity. Int Arch Allergy Appl Immunol. 1976;50(4):473-487.
244. Smith MJ, Garrett RH. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. Inflamm Res. Nov 2005;54(11):435-450.
245. Atkinson JB, Robinowitz M, McAllister HA, Virmani R. Association of eosinophils with cardiac rupture. Hum Pathol. Jun 1985;16(6):562-568.
246. Brivio F, Lissoni P, Barni S, et al. Effects of a preoperative course of interleukin- 2 on surgical and immunobiological variables in patients with colorectal cancer: a phase 2 study. Eur J Surg. Jan 1993;159(1):43-47.
247. Capobianco A, Manfredi AA, Monno A, Rovere-Querini P, Rugarli C. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. J Immunother. Jun 2008;31(5):458-465.
248. Cuschieri A, Talbot IC, Weeden S. Influence of pathological tumour variables on long-term survival in resectable gastric cancer. Br J Cancer. Mar 4 2002;86(5):674-679.
249. Fishel RS, Farnen JP, Hanson CA, Silver SM, Emerson SG. Acute lymphoblastic leukemia with eosinophilia. Medicine (Baltimore). Jul 1990;69(4):232-243.
250. Gonzalez H, Maloum K, Remy F, Merle-Beral H, Lesty C. Cleaved lymphocytes in chronic lymphocytic leukemia: a detailed retrospective analysis of diagnostic features. Leuk Lymphoma. Mar 2002;43(3):555-564.
251. Hagihara M, Miyachi H, Kobayashi H, Ogawa T. Bone marrow eosinophilia as a prognostic indicator in acute myelogenous leukemia with 8;21 translocation. Int J Hematol. Apr 1992;55(2):173-177.
252. Kong YY, Dai B, Kong JC, Lu HF, Shi DR. Neutrophil/eosinophil-rich type of primary cutaneous anaplastic large cell lymphoma: a clinicopathological, immunophenotypic and molecular study of nine cases. Histopathology. Aug 2009;55(2):189-196.
253. Leighton SE, Teo JG, Leung SF, Cheung AY, Lee JC, van Hasselt CA. Prevalence and prognostic significance of tumor-associated tissue eosinophilia in nasopharyngeal carcinoma. Cancer. Feb 1 1996;77(3):436-440.
254. MacDonald WC, Owen DA, Le N. Chronic advanced gastric cancer: clinicopathologic analysis of survival data. Hum Pathol. May 2008;39(5):641-649.
255. Nicolini A, Carpi A, Rossi G. An immunotherapy schedule in endocrinedependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J Immunother. May-Jun 2005;28(3):276-279.
256. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. Dec 1999;189(4):487-495.
257. Romano F, Piacentini MG, Franciosi C, et al. Phase-II randomized study of preoperative IL-2 administration in radically operable gastric cancer patients. Hepatogastroenterology. Nov-Dec 2004;51(60):1872-1876.
258. Utsunomiya A, Ishida T, Inagaki A, et al. Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res. Jul 2007;31(7):915-920.
259. von Wasielewski R, Seth S, Franklin J, et al. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors. Blood. Feb 15 2000;95(4):1207-1213.
260. Marshall PB. Effect of sex hormones on the excretion of free histamine by male and female rats. Br J Pharmacol Chemother. Feb 1961;16:50-58.
261. Chen W, Beck I, Schober W, et al. Human mast cells express androgen receptors but treatment with testosterone exerts no influence on IgE-independent mast cell degranulation elicited by neuromuscular blocking agents. Exp Dermatol. Mar 2009;19(3):302-304.
262. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. Jul 2009;9(7):501-507.
263. Yang N, Zhang H, Si-Ma H, et al. Dexamethasone decreases hepatocellular carcinoma cell sensitivity to cisplatin-induced apoptosis. Hepatogastroenterology. Sep-Oct 2011;58(110-111):1730-1735.
264. Gompel A, Somai S, Chaouat M, et al. Hormonal regulation of apoptosis in breast cells and tissues. Steroids. Oct-Nov 2000;65(10-11):593-598.
265. Elangovan S, Ramachandran S, Venkatesan N, et al. SIRT1 is essential for oncogenic signaling by estrogen/estrogen receptor alpha in breast cancer. Cancer Res. Nov 1 2011;71(21):6654-6664.
266. Tolhurst RS, Thomas RS, Kyle FJ, et al. Transient over-expression of estrogen receptor-alpha in breast cancer cells promotes cell survival and estrogenindependent growth. Breast Cancer Res Treat. Jul 2011;128(2):357-368.
267. Feng X, Jiang Y, Meltzer P, Yen PM. Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol. Jul 2000;14(7):947-955.
268. Tiede S, Bohm K, Meier N, Funk W, Paus R. Endocrine controls of primary adult human stem cell biology: thyroid hormones stimulate keratin 15 expression, apoptosis, and differentiation in human hair follicle epithelial stem cells in situ and in vitro. Eur J Cell Biol. Oct 2010;89(10):769-777.
269. Periyasamy-Thandavan S, Takhar S, Singer A, et al. Insulin-like growth factor 1 attenuates antiestrogen- and antiprogestin-induced apoptosis in ER+ breast cancer cells by MEK1 regulation of the BH3-only pro-apoptotic protein Bim. Breast Cancer Res. Mar 19 2012;14(2):R52.
270. Song RX, Chen Y, Zhang Z, et al. Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol. Feb 28 2010;118(4- 5):219-230.
271. Graham HT, Lowry OH, Wheelwright F, Lenz MA, Parish HH, Jr. Distribution of histamine among leukocytes and platelets. Blood. May 1955;10(5):467-481.
272. Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovascular disease and beyond. Arterioscler Thromb Vasc Biol. Dec 2010;30(12):2357-2361.
273. Gill DS, Barradas MA, Fonseca VA, Gracey L, Dandona P. Increased histamine content in leukocytes and platelets of patients with peripheral vascular disease. Am J Clin Pathol. May 1988;89(5):622-626.
274. Dryden GW, Jr, Deaciuc I, Arteel G, McClain CJ. Clinical implications of oxidative stress and antioxidant therapy. Curr Gastroenterol Rep. Aug 2005;7(4):308-316.
275. Morino K, Petersen KF, Shulman GI. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes. Dec 2006;55 Suppl 2:S9-S15.
276. Bonilla E, Tanji K, Hirano M, Vu TH, DiMauro S, Schon EA. Mitochondrial involvement in Alzheimer's disease. Biochim Biophys Acta. Feb 9 1999;1410(2):171-182.
277. Atkinson SA. Vitamin D status and bone biomarkers in childhood cancer. Pediatr Blood Cancer. Feb 2008;50(2 Suppl):479-482; discussion 486.
278. Flemming GM, Petzold S, Meigen C, Korner A, Kiess W, Kratzsch J. Is Circulating Osteocalcin Related to Adipokines and Overweight/Obesity in Children and Adolescents? Exp Clin Endocrinol Diabetes. Mar 22 2012.
279. Celinski SA, Fisher WE, Amaya F, et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J Surg Res. Nov 2003;115(1):41-47.
280. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation andgrowth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab. Jul 2001;86(7):2976-2981.
281. Frohman LA, Downs TR, Chomczynski P. Regulation of growth hormone secretion. Front Neuroendocrinol. Oct 1992;13(4):344-405.
282. Frohman LA, Downs TR, Kelijman M, Clarke IJ, Thomas G. Somatostatin secretion and action in the regulation of growth hormone secretion. Metabolism. Sep 1990;39(9 Suppl 2):43-45.
283. Hofland LJ. Somatostatin and somatostatin receptors in Cushing's disease. Mol Cell Endocrinol. May 14 2008;286(1-2):199-205.
284. Pedroncelli AM. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide. Neuroendocrinology. 2010;92 Suppl 1:120-124.
285. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology. Apr 1982;110(4):1147-1154.
286. van der Hoek J, Lamberts SW, Hofland LJ. The role of somatostatin analogs in Cushing's disease. Pituitary. 2004;7(4):257-264.
287. Johnston DG, Pernet A, McCulloch A, Blesa-Malpica G, Burrin JM, Alberti KG. Some hormonal influences on glucose and ketone body metabolism in normal human subjects. Ciba Found Symp. 1982;87:168-191.
288. Rask E, Walker BR, Soderberg S, et al. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab. Jul 2002;87(7):3330-3336.
289. Garrod O. The pharmacology of cortisone, cortisol (hydrocortisone) and their new analogues. Postgrad Med J. Jun 1958;34(392):300-304 passim.
290. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ. Jan 2012;19(1):75-86.
291. Speirs CK, Hwang M, Kim S, et al. Harnessing the cell death pathway for targeted cancer treatment. Am J Cancer Res. 2011;1(1):43-61.
292. Walton JC, Weil ZM, Nelson RJ. Influence of photoperiod on hormones, behavior, and immune function. Front Neuroendocrinol. Aug 2010;32(3):303-319.
293. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev. Jun 2003;55(2):325-395.
294. Abe K, Nicholson WE, Liddle GW, Orth DN, Island DP. Normal and abnormal regulation of beta-msh in man. J Clin Invest. Aug 1969;48(8):1580-1585.
295. Tanaka K, Nicholson WE, Orth DN. Diurnal rhythm and disappearance halftime of endogenous plasma immunoreactive beta-MSH (LPH) and ACTH in man. J Clin Endocrinol Metab. Jun 1978;46(6):883-890.
296. Van Cauter EW, Virasoro E, Leclercq R, Copinschi G. Seasonal, circadian and episodic variations of human immunoreactive beta-MSH, ACTH and cortisol. Int J Pept Protein Res. Jan 1981;17(1):3-13.].
297. Charpin C, Argemi B, Cannoni M, et al. [Immunohistochemical detection of calcitonin, ACTH, beta-MSH, beta-endorphin and somatostatin in medullary carcinoma of the thyroid. Immunoperoxidase study (PAP, ABC) of 10 cases]. Ann Pathol. Jan-Mar 1984;4(1):27-35.
298. Kakudo K, Miyauchi A, Katayama S. Ultrastructural study of thyroid medullary carcinoma. Acta Pathol Jpn. Sep 1977;27(5):605-622.
299. Oki S, Nakao K, Tanaka I, et al. Concomitant secretion of adrenocorticotropin, beta-endorphin, and gamma-melanotropin from perfused pituitary tumor cells of Cushing's disease: effects of lysine vasopressin, rat median eminence extracts, thyrotropin-releasing hormone, and luteinizing hormone- releasing hormone. J Clin Endocrinol Metab. Jan 1981;52(1):42-49.
300. Werner SC, Tierney J, Tallberg T. Thyrotro Ic and "Long-Acting Thyroid Stimulator" Effects from Certain Polypeptides. J Clin Endocrinol Metab. Apr 1964;24:339-346.
301. Bowers CY, Redding TW, Schally AV. Effects of Alpha-and Beta-Melanocyte Stimulating Hormones and Other Peptides on the Thyroid in Mice. Endocrinology. Apr 1964;74:559-566.
302. Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocytestimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. Aug 2008;29(5):581-602.
303. Sakel M. Insulin therapy in the future of psychiatry. Can Med Assoc J. Aug 1938;39(2):178-179.
304. Duraffourd C. Introduction á la biologie des fonctions. In: Duraffourd C, Lapraz JC, editors. Traite de phytotherapie clinique: medicine et endobiogenie. Masson ed. Paris: Masson; 201:695-714.